(Q45693995)

15 December 2017

Low-dose methotrexate therapy for ocular inflammatory disease (English)

1 reference

15 December 2017

0 references

1 reference

Shah SS

1

1 reference

15 December 2017

Lowder CY

2

1 reference

15 December 2017

Schmitt MA

3

1 reference

15 December 2017

Wilke WS

4

1 reference

15 December 2017

Kosmorsky GS

5

1 reference

15 December 2017

Meisler DM

6

1 reference

15 December 2017

1 September 1992

1 reference

15 December 2017

1 reference

15 December 2017

99

1 reference

15 December 2017

9

1 reference

15 December 2017

1419-1423

1 reference

The nonspecific orbital inflammatory syndromes

15 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Management of orbital inflammatory disease. A protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Radiotherapy for idiopathic inflammatory orbital pseudotumor. Indications and results

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Treatment of severe Graves' ophthalmopathy with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Immunosuppressive therapy for the eye changes of Graves' disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Cyclophosphamide in the treatment of orbital vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Methotrexate in the treatment of arthritis and connective tissue diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

The pharmacology and clinical use of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Immunosuppressive Effects of Cytosine Arabinoside and Methotrexate in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Antiproliferative effects of methotrexate on peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Response of immunoregulatory lymphocyte subsets to methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Signs and symptoms of uveitis. I. Anterior uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Treatment of uveitis with methotrexate.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Immunosuppressive therapy for external ocular inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Scleritis in relapsing polychondritis. Response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Efficacy of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931790-7

7 January 2021

10.1016/S0161-6420(92)31790-7

Identifiers

DOI

1 reference

15 December 2017

1 reference